Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Aug 17, 2021 2:54pm
119 Views
Post# 33718036

RE:RE:RE:RE:NASH

RE:RE:RE:RE:NASH

THTX didn't let the opportunity go away in fact during the last chat Paul talked more about NASH than other projects now they seems to have an event just for NASH. Good for them. If the board doesn't want to allocate resources to costly NASH that's understandable for a small company like THTX in fact many here always wanted a partnership for the program so they de-risk it and bring more credibility to it.

The legacy analysts are not engaged in any aspect of company's projects some don't even know the oncology trial has started. As for NASH I believe all the U turns is confusing the market and analysts, first HIV then general then partnership so it all should end when they get that partner. Between now and then and beyond a decent measured retail approach would be very helpful.

qwerty22 wrote:

From what I can tell nobody knows what the new OCA 18 month data will look like, I'm not sure it's even complete so Abraham's first comment is pretty vacuous. If you give yourself another roll of the dice you always have a chance of winning, I can't see it going much deeper than that.

It's always safety AND efficacy, getting a clear positive balance for the two. I agree OCA has a safety issue that Egrifta doesn't but Egrifta is way, way behind on proving those Ph3 endpoints.

My point was just how quickly analysts begin hedging their bets when faced with added complexity and uncertainty, but that is obvious I guess. OCA is nothing if not complex and uncertain. I think there are Egrifta parallels there but for different reasons. My guess is that is what stopped them even engaging with the thtx program in the first place.

The X billion dollar market explains why thtx shouldn't just let this opportunity disappear. But how and when they unlock the value is important as well and you have to go deeper into the internals and externals to try to figure that out.  Just saying X billion doesn't get you very far IMO.

 

scarlet1967 wrote:

 

"To RBC Capital Markets, Intercept’s data boost and new trial design will “have much more power" to determine a benefit for obeticholic acid patients, according to a note sent on Thursday. However, it “still remains unclear” exactly how well the treatment has to perform to satisfy regulators, particularly when considering safety, RBC analyst Brian Abrahams wrote."
so their issues are mainly re the safety of the drug, Egrifta is safe.

 

 

qwerty22 wrote:

 

More of that.

https://www.fiercepharma.com/pharma/intercept-still-sees-fda-approval-pathway-for-nash-hopeful-ocaliva-as-long-as-safety-holds

So extending data out to 18 months. That is where fda guidance went at the start of this year. I think we probably should think of THTX's 18 month decision as likely just where things are moving in NASH rather than anything specific to their drug.

Add uncertainty to the picture and RBC's Abrahams gets confused/wants clarity, sound familiar?

 

scarlet1967 wrote:

 

Despite the recent setbacks many companies still are trying to develop a drug for the condition. For instance Intercept with a drug with serious safety issues still is trying to get it approved.
Reason is NASH is multi billion dollar market with growing prevalence and unmet. 

https://www.clinicaltrialsarena.com/analysis/intercept-nash/


 

 




<< Previous
Bullboard Posts
Next >>